Our potential impact is beyond measure

We are committed to the discovery and development of a transformational generation of targeted therapies for women’s cancers. Led by a team of professionals with a deep understanding of endocrine-driven cancers and extensive development expertise, we are persistent in our pursuit of advancing  the standard of care for women living with cancer.

Our Team leadership board of directors
leadership
board of directors
leadership
Sean P. Bohen, M.D., Ph.D. President and CEO
cross
Shane Kovacs Chief Operating and Financial Officer
cross
Naseem Zojwalla, M.D. Chief Medical Officer
cross
David C. Myles, Ph.D. Chief Discovery and Non-Clinical Development Officer
cross
Julie Dexter Senior Vice President and Head of People
cross
Sasha Austin, CPA Vice President, Finance and Controller
cross
Demiana Faltaos, PharmD, Ph.D. Vice President, Head of Clinical Pharmacology
cross
Richard Hernandez Vice President, Clinical Development Operations
cross
Kamesh Kuchimanchi, Ph.D. Vice President, Regulatory Affairs and Quality Assurance
cross
Kristin Lanzi Vice President, Information Technology
cross
Geoffrey Mogilner Vice President, Investor Relations and Communications
cross
Gopinath Palanisamy, DVM, Ph.D., DACVP Vice President, Pre-Clinical Pharmacology and Toxicology
cross
Mark Shilkrut, M.D., Ph.D. Vice President, Clinical Development
cross
Margaret Tonda, PharmD Vice President, Clinical Science
cross
Rachel Wei, Ph.D. Vice President, Biostatistics
cross
Jim Zhang, Ph.D. Vice President, CMC
cross
Sean P. Bohen, M.D., Ph.D. President and CEO
cross
Ian Clark Chairman of the Board
cross
Cindy Butitta Member
cross
Scott Garland Member
cross
Cyrus Harmon, Ph.D. Member
cross
Sandra J. Horning, M.D., FACP, FASCO Member
cross
Gorjan Hrustanovic, Ph.D. Member
cross
Yi Larson, MBA Member
cross
Andy Rappaport Member
cross
Graham Walmsley, M.D., Ph.D. Member
cross

Learn more about our values.